189 results about "Cysteine Proteinase Inhibitors" patented technology

PCT No. PCT / GB96 / 01707 Sec. 371 Date Feb. 26, 1998 Sec. 102(e) Date Feb. 26, 1998 PCT Filed Jul. 17, 1996 PCT Pub. No. WO97 / 04004 PCT Pub. Date Feb. 6, 1997The invention provides compounds for use in the treatment of allergic diseases including juvenile asthma and eczema. The compounds can inhibit IgE mediated reaction to major environmental and occupational allergens and can also have a prophylactic effect against allergic disease by preventing allergic sensitization to environmental and occupational allergens when administered to at-risk individuals (e.g., those at genetic risk of asthma and those exposed to occupational allergens in the workplace). The compounds are also useful for inactivation or attenuation of the allergenicity of allergens in situ. The invention provides compounds and ligands per se, pharmaceutical compositions containing the compounds, processes for producing the compounds and pharmaceutical compositions, and methods for using the compounds and compositions in treatment or prophylaxis of IgE mediated allergic diseases and in inactivation or attenuation of allergens in situ. The invention also enables the reduction or destruction of the viability of allergy-causing organisms.

The invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject. The method comprises administering to the nervous system of the subject a composition comprising a thyroxine protein or a therapeutic fragment or pharmacologic mimic thereof and a pharmaceutically acceptable carrier. The invention also provides a method for treating ALS in a subject that comprises administering to the subject a transthyretin protein, 7B2 protein, a cystatin C protein, a neuroendocrine protein, a cysteine protease inhibitor, or an inhibitor of an enzyme that processes a 7B2 protein. In addition, the invention provides methods for determining the susceptibility of a subject to developing ALS and for determining the progression of ALS in a subject.

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

This invention relates to class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis. They have the following structure: Formula (I)

The invention relates to a triazine compound with a structure represented by a formula A, or a stereoisomer, a prodrug, an active metabolite or a pharmaceutically acceptable salt, a solvate or a crystal form thereof, a pharmaceutical composition of the triazine compound, the stereoisomer, the prodrug, the active metabolite or the pharmaceutically acceptable salt, the solvate or the crystal form, and a use method of the triazine compound. In addition, the invention also relates to a method for preparing a 3C-like cysteine protease inhibitor or a medicine for treating and / or preventing virus infectious diseases. In particular, the present invention relates to the use for treating viral infectious diseases such as Middle East Syndrome Related Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome Related Coronavirus (SARS-CoV), Influenza A virus, Influenza B virus, Novel Coronavirus Pneumonia (COVID-19) and the like.

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

There is a demand for improved turbidimetric immunoassays for human Cystatin C in biological samples, especially in human clinical samples of body fluids. The present invention provides a turbidimetric immunoassay method and reagent set enabling measurement of human Cystatin C by turbidimetric methods, resulting in a surprisingly stronger and faster turbidimetric signal than in the present state of the art. The increased and faster signal is accomplished by the use of new reagents and compositions, and enables shorter assay times and kinetic reading with a stronger signal, improving overall assay speed and quality. Improved robustness to lipid interference and improved linearity is achieved.

The invention relates to an immunoturbidimetry kit for detecting a cysteine proteinase inhibitor C and a preparation method thereof. An application liquid bottle, an antibody suspension liquid bottle and a standard substance bottle are placed in a box body; an application liquid is filled in the application liquid bottle and comprises the following components: 0.01-2% of surfactant, 0.01-1% of preservative, 0.1-20% of sodium chloride and 10-200 mmol / L of buffer solution; a latex suspension liquid coated with a monoclonal antibody of the cysteine proteinase inhibitor C is filled in the antibody suspension liquid bottle and comprises the following components: 0.05-1% of latex coated with the monoclonal antibody of the cysteine proteinase inhibitor C, 0.01-2% of surfactant, 0.01-1% of preservative and 10-200 mmol / L of buffer solution; and a standard substance of the cysteine proteinase inhibitor C is filled in the standard substance bottle. The purpose of large-batch quantitative detection on a biochemical instrument is achieved.

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

Compounds of the formula II:whereinR2 is the side chain of leucine, isoleucine, cyclohexylglycine, O-methyl threonine, 4-fluoroleucine or 3-methoxyvaline;R3 is H, methyl or F;Rq is trifluoromethyl and Rq′ is H or Rq and Rq′ define keto;Q is a p-(C1-C6alkylsulphonyl)phenyl- or an optionally substituted 4-(C1-C6alkyl)piperazin-1-yl-thiazol-4-yl- moiety have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.